IP Library › Granted Patent US 9,096,901
Granted Patent B2
US 9,096,901 · App. 13/603,109 · Granted Aug 4, 2015

Methods and materials related to hair pigmentation and cancer

Inventors: Leif Andersson (Uppsala, SE); Gerli Rosengren Pielberg (Uppsala, SE); Anna Olegovna Golovko (Uppsala, SE); Kjell Robert Johan Lennartsson (Heby, SE); Carl-Henrik Heldin (Uppsala, SE)
Assignee: Biocistronix AB
C12Q1/6881C12Q1/6886C12Q2600/124C12Q2600/136C12Q2600/156C12Q2600/158C12Q2600/172
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,096,901
App. No.
13/603,109
Granted
Aug 4, 2015
Kind
B2
Abstract

This document relates to methods and materials for determining whether or not a horse contains a Grey allele. For example, diagnostic methods such as nucleic acid-based detection methods and materials such as nucleic acid probes and primer pairs that can be used to determine whether or not a horse contains a duplication in intron 6 of STX17 nucleic acid are provided. This document also relates to methods and materials for treating a mammal having or being likely to develop cancer (e.g., benign, malignant, or metastatic cancer). For example, methods and materials for treating cancer in a mammal by administering an agent having the ability to reduce expression of an STX17 polypeptide and/or an NR4A polypeptide (e.g., an NR4A1, NR4A2, or NR4A3 polypeptide) in the mammal are provided.

Claims (6)

1. A method for treating a mammal having cancer, wherein said method comprises administering, to said mammal, a composition comprising an agent having the ability to reduce an STX17 polypeptide activity in said mammal.

2. The method of claim 1 , wherein said mammal is a horse.

3. The method of claim 1 , wherein said mammal is a human.

4. The method of claim 1 , wherein said cancer is a melanoma.

5. The method of claim 1 , wherein said agent comprises a nucleic acid molecule capable of inducing RNA interference against expression of a STX17 polypeptide.

6. The method of claim 1 , wherein said agent comprises an anti-STX17 antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2015
From: MELICA HB
To: BIOCISTRONIX AB
Reel/Frame 035719/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2013
From: ANDERSSON, LEIF; PIELBERG, GERLI ROSENGREN; GOLOVKO, ANNA OLEGOVNA; LENNARTSSON, KJELL ROBERT JOHAN; HELDIN, CARL-HENRIK
To: MELICA HB
Reel/Frame 030603/0278 →
Continuity (3)
Continuation 12663138
Provisional Application 60942080 · Jun 5, 2007
Related Publication 20130004520A1 · Jan 3, 2013